{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:17:33Z","timestamp":1788524253208,"version":"build-2803163510"},"reference-count":14,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"published-print":{"date-parts":[[2024,6]]},"abstract":"\n Introduction<\/jats:title>\n This case series reports on five patients with opioid use disorder (OUD) who were commenced directly onto high-dose long-acting injectable buprenorphine (LAIB).<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n A retrospective audit and manual review of the electronic medical record at cohealth Innerspace was conducted for patients who had been directly inducted onto high-dose LAIB.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Five cases were identified on retrospective manual file review. All patients identified were males aged between 33 and 60 years old and were treated with either high-dose Buvidal Weekly and Monthly preparations. No immediate significant adverse effects were noticed and 4 out of 5 remain engaged with treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This case series shows it is possible to directly induct patients with OUD onto high-dose LAIB preparations without significant side effects or harm to the patient and could be considered a viable option in the treatment of patients with OUD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10398562241237655","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:34:04Z","timestamp":1709696044000},"page":"238-241","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Direct induction onto high-dose long-acting injectable buprenorphine: A case series"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-3696","authenticated-orcid":false,"given":"Thileepan","family":"Naren","sequence":"first","affiliation":[{"name":"Drug Health Services, Western Health, Footscray, AU-VIC, Australia; and"},{"name":"Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Cook","sequence":"additional","affiliation":[{"name":"Drug Health Services, Western Health, Footscray, AU-VIC, Australia; and"},{"name":"Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"MacCartney","sequence":"additional","affiliation":[{"name":"Cohealth\u2009Innerspace, Collingwood, AU-VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"bibr1-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.021"},{"key":"bibr2-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786"},{"key":"bibr3-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2676"},{"key":"bibr4-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128"},{"key":"bibr5-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636"},{"key":"bibr6-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"bibr7-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"bibr8-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108959"},{"key":"bibr9-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108776"},{"key":"bibr10-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13161"},{"key":"bibr11-10398562241237655","unstructured":"The cohealth model. Published May 14, 2023. https:\/\/www.cohealth.org.au\/about-us\/our-organisation\/the-cohealth-model\/ (Accessed May 15, 2023)."},{"key":"bibr12-10398562241237655","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2022.05.032"},{"key":"bibr13-10398562241237655","volume-title":"Heroin toxicity","author":"Oelhaf RC","year":"2022"},{"key":"bibr14-10398562241237655","unstructured":"Lintzeris PN, Dunlop A. Brief Clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence. Australia: NSW Health."}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562241237655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10398562241237655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562241237655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:52:32Z","timestamp":1777377152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10398562241237655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1177\/10398562241237655"],"URL":"https:\/\/doi.org\/10.1177\/10398562241237655","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}